Delays in childbirth injury diagnosis are impacting women's mental health, survey finds
A long bike ride to the park is Kristy Keefe's idea of a perfect day with her sons.
She relishes every precious moment, having missed out on too many years ago when a traumatic birth led to a mental health collapse.
"I have pictures and I am like I don't remember that," she says. "Because I was there, but I wasn't there."
Kristy says she has blocked out some memories after hitting "rock bottom" when her second child was unexpectedly born in the hallway of her home six years ago.
The trauma of her son Riley's birth, coupled with a fourth-degree vaginal tear, triggered feelings of dread and isolation.
"I was really anxious. I really didn't want to be in the house because that's where it happened," she says.
"I didn't want to be left alone with my baby by myself," Kristy remembers, saying she was having intrusive thoughts about something awful happening to her child.
"I just felt really vulnerable and unsafe. It went to rock bottom."
For women's health leaders like obstetrician Nisha Khot, Kristy's story cuts deep.
"It's just a sign that we have failed women," Dr Khot says.
Perinatal Anxiety and Depression Australia says one in three women experience a traumatic birth, with injuries including pelvic floor damage, perineal tears, episiotomy, incontinence, pelvic organ prolapse, as well as psychological distress.
Understanding the impact of those birth injuries was the focus of a new survey from advocacy group Birth Trauma Australia (BTA).
Nearly 400 women from around the country were asked questions about their birth experience, injuries sustained, diagnosis of the injuries, pain issues, incontinence and mental health.
BTA chief executive Amy Dawes says the longer birth injuries take to diagnose, the more catastrophic the consequences.
"We found that women that had struggled to get a diagnosis, they were 2.4 times more likely to experience suicidal thoughts," Ms Dawes says.
"It's a taboo within a taboo. I have … heard firsthand accounts of women sharing their experiences of being in a really dark place following their birth trauma and struggling to get care, being dismissed."
The new research also found almost all (98 per cent) of those who experienced birth-related trauma reported ongoing physical injury or pain that was not managed.
It found that distressing or emergency procedures (69.6 per cent) and poor management of pain or physical injuries (53.8 per cent) are the most significant contributors to birth trauma and can lead to significant mental health impacts.
Improving the mental wellbeing of women after a traumatic birth is a top priority for Dr Khot, president-elect of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).
"If you have physical trauma and you're struggling with your body functions, then that is going to affect you psychologically as well, so it's not as if they're two separate entities," she says.
Dr Khot says, while shocking, the survey results do not surprise her.
"You just had your first baby and suddenly you find that you are incontinent," she says.
"That has such huge implications for you to be able to just lead a normal life … go out with family, look after your baby, hold your baby, just lift your baby.
"You can't do any of these things because of your incontinence. That is bound to have a huge impact on your mental wellbeing. How could it not?"
It has been more than a year since a landmark inquiry in New South Wales heard traumatic birth experiences can have tragic consequences, including suicide and suicidal ideation.
The inquiry found a number of women suffered preventable birth trauma in NSW and urgent efforts must be made to address it.
BTA says there is now more investment and education of healthcare workers in the space, but more is needed.
Misdiagnosis and delays in diagnosing birth-related injuries were also examined during the inquiry.
BTA survey participant and mother-of-two Kristy says she struggled to get professional support in the public system for her incontinence, which compounded her psychological distress.
She says it was disappointing to be out of pocket, but feels the private gynaecology, psychology and physiotherapy expertise she received was crucial to her mental and physical recovery.
"I feel that if I didn't go and get that help and paid all that money … that maybe I wouldn't be here today."
Ms Dawes says Kristy's experience is common.
"Everyday women and birthing people across Australia are falling through the gaps in care," she says
"They're sustaining severe, sometimes preventable, injuries and they fall through the gaps in a fragmented healthcare system."
RANZCOG, BTA and the Australian College of Midwives are developing a federal government-funded birth trauma education pilot project, which will guide clinicians in prevention and rehabilitation of birth-related trauma.
BTA is also advocating for mandatory postnatal screening and more funding for psychological support and physiotherapy.
In its most recent budget, the New South Wales government allocated an extra $83 million for maternity care, family care centres and maternal vaccination.
Victoria is spending an extra $21 million on its perinatal mental healthcare program.
The Queensland government launched an $11 million women's wellbeing line this year and is also funding 30 new mother and baby beds for in-patient treatment of severe perinatal mental health disorders.
In Western Australia, the NSW inquiry has prompted the development of a birth trauma policy for its public hospitals.
Incoming RANZCOG president Nisha Khot says she will be urging her obstetrician colleagues to prioritise the issue.
"We should not forget that the reason we do what we do is because we want to support women. We want women to have good experiences and good outcomes," she says.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
2 hours ago
- News.com.au
Dr Boreham's Crucible: Microba Life Sciences
When Russian author Aleksandr Solzhenitsyn said the battle between good and evil runs through every man - ok, person - he was not talking about the trillions of bacteria that reside in the gut. But he may well have been, because this thriving ecosystem of bugs can make us very ill - or promote healthy functions such as digestion and immunity. In the main, they do the good stuff. Microba's reason for being is to help chronically unwell people by addressing their microbiome, which CEO Dr Luke Reid dubs the critical 'missing organ'. Gut health and the microbiome have been a trendy 'wellness' area, exemplified by the proliferation of probiotic supplements. 'But no one has truly medicalised the unequivocal science that has built over the last decade on this forgotten organ, and how we can treat and manage it,' Reid says. Microba has commercialised two clinical tests, to assess and manage gastro-intestinal (GI) patients. 'We have been at the forefront of clinical microbiome diagnostics for the last seven years,' the CEO says. Microba spawns from the germ of a good idea Reid says Brisbane-based Microba 'sits at the intersection of the integrity of the gastro-intestinal tract, the structure and function of the microbiome, and the communication between the brain and the gut.' The company's flagship Metaxplore tests assess a range of markers to assess the gastro-intestinal tract. 'It then distills that into a clear report with findings and - most importantly - what the clinicians can in terms of diet, dietary supplementation, targeted medications and specific lifestyle changes,' Reid says. Microba was formed in 2017 based on intellectual property acquired from the University of Queensland. The patents built on the work of the co-founders Prof Philip Hugenholtz and Prof Gene Tyson at institutions including University of California Berkeley, Massachusetts Institute of Technology and the Joint Genome Institute. Reid was an associate director of Uniquest Pty Ltd and held roles with plant genetics leader Dupont Pioneer, and biotechnology innovator Novozymes. The company's deputy chair, Prof Ian Frazer, co-invented the Gardasil and Cervarix cervical cancer vaccines. The company launched its first non-diagnostic product, Microba Insight, in Australia in July 2018. This delivered the world's 'largest clinically applicable, proprietary microbiome dataset'. Microba listed on April 5, 2022, at a subscription price of 45 cents, with the initial public offer raising $30 million. The company launched its core clinical testing products Metaxplore and Metapanel, in February 2023 and March 2024 respectively (see below). In November 2023, Microba expanded into the UK with the strategic acquisition of private UK microbiome testing business Invivo Clinica, for an upfront GBP5 million ($A10.4 million). In late 2022, ASX-listed pathology giant Sonic Healthcare invested $17.8 million to acquire a 19.99% holding in Microba. In October 2024, the company sold its non-core research services business and this year has been discontinuing legacy products. In late April, Microba entered a partnership with the Colonoscopy Clinic, one of Australia's largest private gastro-intestinal operations, seeing about 10,000 patients a year. The guts of Microba The Microba business is based on a proprietary database of one million microbial genomes, covering thousands of species. Rather than 'dying in a sea of opportunity', the company has focused on gastro-intestinal disease. 'Ninety-five per cent of those organisms live in the gut and will act there first, before they have their systemic impact through the body,' Reid says. Metapanel is the 'first line' test to determine whether the patient has a pathogen that can be treated simply with antibiotics. While other screening panels are available, they only detect 15 to 25 pathogens, whereas Metaxplore can deal with more than 100. 'Metapanel rules out the simplest root causes first - 'bad guy? yes or no' - while Metaxplore deals with the complexity of everything else that could be wrong with that patient's gastro-intestinal and microbiome health,' Reid says. As with a standard pathology assay, clinicians refer both tests to patients. The patient sends back a stool test sample with the supplied kit. The clinicians interpret the reports - which are designed to be 'simple and actionable' - just before the patient visits. Metapanel study In May, Microba released the 'compelling' results of a study called Metapanel, which analysed 889 test results from patients' long-term gastro-intestinal symptoms. The results showed that 20% of patients (178 of them) tested positive for a pathogen that can cause gastro-intestinal infection. Of the pathogens detected, 78% were missed by routine pathology tests. Furthermore, 58% of tests showed abnormal microbiome results, supporting referral to a Metaxplore test for further investigation. All the patients treated showed 'complete symptom resolution' in an independent study. All results are reviewed by an expert pathologist that recommends treatments, including antibiotic selection. Metaxplore study A week later, Microba announced the results of a 'landmark' gastro-intestinal study, covering more than 4600 patients undergoing Metaxplore testing. Of these, 71.4% had 'actionable results' with 42% testing positive for abnormal microbiome markers linked to gastro-intestinal health. About 10% tested positive for gastro-intestinal markers, such as inflammation, pancreatic insufficiency or stool blood. Almost 20% tested positive for multiple markers (microbiome and gastro-intestinal). The crux is that 65% of patients reported health improvements after following their doctor's advice (based on the Metaxplore findings). Eyes on the US prize Currently Metaxplore is sold in Australia and in the UK, while Metapanel is available locally via Sonic. Reid says Microba has a 'well considered plan' for US rollout. 'The US market is a big pie, so we have a plan to take it one slice and one bite at a time,' Reid says. 'Our strategy is to start in one state and one city, with a small team. In effect we will replicate what we did in the UK, accessing influential clinicians and then opening up to more.' The company estimates a total addressable market of $25 billion covering 82 million patients, across the US, the UK, Germany, Italy, Spain, France and Australia. 'Bugs as drugs' For the last five years, Microba has developed a pipeline of novel therapeutics across three programs. Think of them as prescription probiotics, or 'bugs as drugs'. The company has completed a phase I study for ulcerative colitis; and has pre-clinical programs for immune-oncology and auto-immune conditions. Ulcerative colitis is one of the two major forms of irritable bowel disease, which results in inflammation and ulcers (sores) in the digestive tract. It is a debilitating, chronic condition - and poorly treated. In December 2023, the company reported the phase I study of 32 healthy volunteers, showing Microba's drug candidate MAP-315 was 'well tolerated at both low and high doses'. The company plans an investigational new drug application to the US Food and Drug Administration, to enable a phase II trial. Finances and performance In late June, Microba completed a $14.5 million capital raise, with a $12.5 million two-tranche placement and a fully-underwritten share plan for $2 million, both at nine cents a share, a 22% discount. The shares come with options, exercisable at 14 cents within two years. Sonic Healthcare ponied up $4.1 million and has indicated a further potential commitment of $4.1 million more. Microba posted record core test sales in the March quarter. Locally, the company sold 3,225 Metaxplore tests, more than triple the previous period, taking the annualised run rate to 12,900 tests, also up 200%. In the UK, the company sold 246 Metaxplore tests, with turnover doubling between February and March. Meanwhile, the company achieved 212 local Metapanel sales, up 1,827%. Cash receipts totalled $4.23 million for the quarter, up 5.2% on a year previously. Revenue fell 14% to $3.4 million, reflecting an 84% decline in (legacy) research work. Microba guided to revenue of $15.25 million to $16.25 million for the year to June 30, 2025, and in late June narrowed this to $15.4 million to $16 million. Management expects Australia and the UK to be break-even this year. Post raising, the company has a proforma cash position of $26.29 million. Over the last 12 months, Microba shares have wavered between 32 cents (January 28, 2025) and eight cents (July 2 this year). The Microba register includes Thorney Investments (Tiga Trading) and Perennial Value Management. Who's payin' … just sayin' Normally patients are like your columnist with the first shout: short arms and long pockets. Unlike most medical diagnostic plays, Microba is not exactly hanging out for US reimbursement because patients are willing to stump up because they're in so much long-term pain. 'We don't need it to have a ginormous business,' Reid says. 'There is a hungry, cash-pay market that's bigger than people understand.' That said, the company wouldn't exactly snub US reimbursement. Microba's price modelling settled on $470 for Metaxplore in Australia. In the UK, the price is £399 ($A830) per test. In the US, the price looks like coming in at anywhere between US$450 and US$800 ($688 to $1224). Currently sold just in Australia via Sonic, a Metapanel test sells for $345. The obvious gambit is to bundle the tests in a 'two-for-one' special, involving only one medical consultation. This is something for the future. Dr Boreham's diagnosis: Reid says after years of work and investment, Microba has transitioned from being 'R&D heavy' to 'capital light, partnering and revenue-focused'. 'We have a significant revenue base that is growing quickly,' he says. 'We aren't waiting for the promise of approvals or reimbursement; we have real product in the market getting value and delivering clinical results.' While Microba estimates a US$25 billion a year market for 82 million tests, it hones the 'addressable' market within three years to 18 million tests and an 'obtainable' market of two million assays. Do the sums and the revenue rewards are still humungous. In the US alone, 37 million patients present each year with a range of symptoms and half of them are not resolved. 'We only need to unlock a fraction of a percent to meet our business objectives,' Reid says. In the meantime, Microba shares have more than halved over the last year and a crica $50 million valuation does not do justice to these achievements. But in the pantheon of ASX biotechs, this is not a unique story and patient investors should be rewarded in the fullness of time. At a glance: ASX Code: MAP Share price: 9.4 cents Market cap: $48 million Chief executive officer: Dr Luke Reid


SBS Australia
3 hours ago
- SBS Australia
Sugar alternatives are on the rise. They might not be so sweet for the environment
Artificial sweeteners are popular in Australia, with more than one tonne of them consumed daily across the country and food manufacturers increasingly pivoting to sugar-free soft drinks and confectionery. But a new study suggests that the environment might be paying the price for the rise of popular sugar substitutes, with the alternatives building up in waterways around the world. The research, published in the Journal of Hazardous Materials, was led by University of Technology Sydney's Dr Xuan Li. Researchers examined the type and prevalence of artificial sweeteners in wastewater treatment plants across 24 countries, as well as changes in concentration and how effectively they were removed. It found widely used sugar substitutes are not decomposing, and are turning into 'forever chemicals' that are comparable to polyfluoroalkyl substances (PFAS) in their potential harm to animals and the environment. LISTEN TO SBS News 14/07/2025 04:29 English PFAS are a group of man-made chemicals commonly used in water-resistant and non-stick items. They have been identified in a growing body of research as a toxin and carcinogen with proven negative impacts on the environment and human health. Why do sweeteners cause a problem? Unlike natural sugars, artificial sweeteners are designed to resist digestion and not be fully absorbed by the human body. For the same reason, they don't break down as easily in waterways or on the land, and can enter wastewater systems that aren't equipped to deal with them through standard treatment processes. "Whatever we are eating will eventually discharge into wastewater and become concentrated in wastewater treatment plants," Li said. "Our treatment plants are not easily able to degrade them as well. So they will be directly discharged into the environment. And this will gradually lead to the accumulation in the environment and eventually effect all the water creatures." Artificial sweeteners are not fully absorbed by the human body. Source: Getty / Juanmonino/iStockphoto Li said that some fish may die early as a result, and that represented a potentially big problem in the ecosystem. "The bottom line is anything changing the fish will eventually impact the upper food chain and impact other creatures. We have found algae can be impacted, and they all of a sudden bloom, and all of a sudden die, because of the build-up of artificial sweeteners." Were all sweeteners equally harmful? No. One product scored worst when it came to its ability to decompose (or lack thereof) — sucralose, which is marketed as Splenda in supermarkets around the world. Acesulfame, also known as Ace K, was also harder to remove and was released into the wider environment. Two other sweeteners, saccharin and cyclamate, were comparatively easy to remove from water, the study found. These four substitutes were found to be the most prevalent artificial sweeteners. Other artificial sweeteners found in wastewater included neotame, stevia and neo hesperidin dihydrochalcone (NHDC). What could the potential impact be? Li says its impossible to know how long it will take for the build-up of these microtoxins to have a detrimental impact on humans — and to know how severe that impact could be. She said that while there has been much focus on PFAS in recent years, artificial sweeteners have a similar "accumulation pathway" in our environment and in drinking water, affecting organisms. Li said more research needs to happen to determine the impact of sweeteners on our planet, ecosystem and personal health. The study calls for ongoing monitoring, tighter regulations and improved treatment technologies to reduce the potential environmental risks artificial sweeteners pose. In the meantime, Li said we each have a choice. "As consumers ourselves, we can think twice when we are trying to purchase a product," Li said. "I know artificial sweeteners can sound very tempting if you're trying to control your blood sugar level, your body weight. But the question is, do we really understand them well enough? If not, maybe the conventional sugary stuff will be a better solution."

ABC News
4 hours ago
- ABC News
Thousands from LGBTQI+ and sex worker communities can now donate plasma
Thousands of members of the LGBTQI+ and sex worker communities can now donate plasma in Australia without having to wait three months from the last time they had sex. On Monday, Australian Red Cross Lifeblood removed most wait time restrictions for gay and bisexual men, transgender people, sex workers and those on the common HIV prevention drug pre-exposure prophylaxis (PrEP). This change means an estimated 625,000 additional Australians are now eligible to donate plasma. Often referred to as the "liquid gold" part of blood, plasma is used to treat more than 50 medical conditions. During the HIV crisis in the 1980s, Australia introduced an indefinite ban on men who have sex with men from donating blood and plasma in order to prevent transmission through blood transfusion. Skye McGregor from the Kirby Institute said this was in part due to the lengthy time it took to confirm if HIV was present in test results. "To have no deferral now around sexual activity through the plasma pathway is really significant," Dr McGregor said. Other factors such as a 33 per cent drop in HIV diagnoses since 2014, and increased sensitivity of HIV tests — which can detect an infection within a week — have also contributed to the lifting of restrictions. "Whilst these changes were necessary in the past to ensure that blood safety, we also know that they did contribute to stigma within particularly the gay and bisexual community," Lifeblood chief executive officer Stephen Cornelissen said. From July 14, people in these previously restricted groups can donate plasma immediately, regardless of sexual activity. The only exception is for those who've recently had sex with a partner known to have HIV or another blood-borne virus. "It's a beautiful moment," Joshua Smith said, who donated for the first time on Monday. "Blood and plasma donations was one of the last things it felt like gay and bisexual people and trans communities were excluded from. Fellow donor Kane Wheatley added: "It's one of those things that you spend your whole life thinking this is just not going to get across the line, and when it does it feels really nice to be able to be here to support it, normalise it for people as well." Lifeblood estimates an additional 625,000 Australians may now be eligible to donate plasma. It is hoping for 24,000 new donors and 95,000 additional donations a year. The next step is for gay, bisexual and other members of the LGBTQI+ community to be able to donate what's known as "whole blood", not just plasma. The Therapeutic Goods Administration (TGA) has recently approved a gender-neutral risk assessment for blood and platelet donations, which is the first step in the process. This means everyone — regardless of gender or sexual orientation — will be asked if they have had sex (excluding oral sex) with a new or more than one partner in the past six months. If they answer yes, they will be asked whether this included having anal sex in the past three months. Anyone who answers yes will be deferred from donating blood for six months, but will be able to donate plasma. This means gay and bisexual men in long-term, monogamous relationships will be able to donate whole blood without abstaining from sex. This change will be implemented sometime next year, Adjunct Professor Cornelissen said. Let Us Give, a campaign to ensure equality when it comes to blood donation, welcomed the change to giving plasma but said the whole blood rules remain "discriminatory" as they stand currently. Spokesperson Rodney Croome said policy should centre on "the safety of a donor's sexual activity rather than the gender of their sexual partner". He said an approach change like this would "open up a new source of safe blood for those in need and remove discrimination from Australia's blood collection system". Those who have recently had sex with a partner known to have HIV or another blood-borne virus will still be unable to donate blood or plasma. There are also restrictions that prevent people taking some medications, those who have medical conditions such as MS or cancer, people who are pregnant or less than nine months postpartum, and those who have recently undergone surgery from making donations. The rule preventing people who lived in the UK between 1980 and 1996 from donating in Australia was lifted in July 2022.